Simcere Xiangrui's Recombinant Group B Meningococcal Vaccine (Expressed in E. coli) Receives CDE Clinical Trial Acceptance

(Source: PharmaTime)

On May 14, 2026, the latest announcement on the official website of the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) showed that Beijing Simcere Xiangrui Biological Products Co., Ltd.Recombinant Group B Meningococcal Vaccine (E. coli)The clinical trial application has been officially accepted, with the acceptance number CXSL2600529, and the registration category is Class 2.2 preventive biological product. This isThe First Recombinant Group B Meningococcal Vaccine in China Using an E. coli Expression System Submitted for Clinical Trials, marking a significant addition of core strength to the development of domestically produced Group B meningococcal vaccines in China. This brings the country one crucial step closer to completely breaking the monopoly of imported vaccines and filling the gap in China's meningococcal prevention and control system.

Group B Meningococcal Disease Has Become the Top Meningococcal Threat in China, Lack of Domestically Produced Vaccines Calls for Urgent Solutions

Epidemic Cerebrospinal Meningitis ("ECSM" for short) is an acute respiratory infectious disease caused by Neisseria meningitidis, which hasAcute onset, rapid progression, high mortality, severe sequelaeOne of the key infectious diseases prioritized for prevention and control in the field of global public health. Even after standardized treatment, the case fatality rate for meningococcal disease remains as high as 10%-15%. Approximately 10%-20% of survivors are left with permanent neurological sequelae such as intellectual disability, hearing loss, and limb paralysis, causing irreversible harm to individuals and families.

In recent years, the epidemic profile of meningococcal disease in China has undergone a fundamental change. With the widespread vaccination of serogroups A, C, and ACYW135 meningococcal vaccines, the incidence rates of these serogroups have significantly decreased, butThe proportion of Group B meningococcal disease continues to soar.，which has now become the absolute mainstream serogroup of meningococcal disease in China. The latest data from the Chinese Center for Disease Control and Prevention shows that the proportion of reported cases of serogroup B meningococcal disease in China in 2024 has reached67.29%, among which children under the age of 5 are the highest-risk group, making the prevention and control situation particularly severe.

However, as of May 2026,China has not yet approved any domestically developed Group B meningococcal vaccine for marketing.Currently, only GSK's Bexsero has been approved for import in 2023 in the Chinese market, and it has three major obvious shortcomings, making it difficult to meet the prevention and control needs in China:

High price:The full-course vaccination costs approximately 3,000 to 4,000 yuan, far exceeding the affordability of most ordinary families, resulting in extremely low vaccine accessibility;

Insufficient strain coverage: Mainly designed for the epidemic strains in Europe and America, it has limited cross-protection effect on the cc4821 clone cluster, which accounts for the highest proportion in China, and insufficient protective targeting;

Production capacity constrained: The supply of imported vaccines is unstable, making it difficult to meet the large-scale vaccination needs nationwide in China, and a comprehensive prevention and control barrier cannot be formed.

The long-term absence of domestically produced Group B meningococcal vaccine has become a significant短板 in China's public health prevention and control system. Developing a domestically produced Group B meningococcal vaccine that is suitable for the Chinese population, economically accessible, and provides precise protection has become an urgent necessity.

Simcere Xiangrui: E. coli Expression System Creates Cost-Effective Chinese-Manufactured Vaccines

Simcere Xiangrui's recent clinical application for the recombinant Group B meningococcal vaccine adoptsMulti-component Recombinant Protein Technology RouteAndMature E. coli Expression System, is a type 2.2 modified biologic product optimized for locally prevalent strains in China, precisely meeting the prevention and control needs within the country.

The development of Group B meningococcal vaccine is a globally recognized challenge in the industry. Due to the high similarity between the capsular polysaccharide of Group B Neisseria meningitidis and the structure of human neural cell adhesion molecules (NCAM), traditional polysaccharide vaccines not only have weak immunogenicity and fail to effectively induce protective immunity, but also pose a risk of triggering autoimmune reactions. Therefore, the mainstream Group B meningococcal vaccines currently available worldwide utilize recombinant protein technology, safely and efficiently inducing protective immunity by expressing conserved bacterial surface protein antigens.

The core competitiveness of Sinopharm's Xiangrui vaccine is mainly embodied in itsE. coli expression systemAndLocalized Antigen DesignTwo Major Advantages:

Mature process, huge production capacity potential: E. coli is the most widely used and technically mature expression system in the biopharmaceutical field currently, with simple and controllable production processes, easy scalability, and the ability to quickly meet the capacity demands for large-scale vaccination across China;

Significant Cost Advantage: Compared with expression systems such as yeast and mammalian cells, the production cost of the E. coli expression system can be reduced by more than 50%. After its future market launch, the full-course vaccination price is expected to be controlled within 1,000 yuan, significantly improving vaccine accessibility.

Localization of Strain Matching: Targeted screening of mainstream clones prevalent in China, such as cc4821 and cc32, optimizing antigen design, is expected to yield better protective effects than imported vaccines, aligning more closely with the prevention and control needs of the Chinese population;

Good safety profile: The E. coli expression system has no risk of potential viral contamination, the product quality is stable and controllable, and its safety has been verified by decades of clinical applications. It can be safely used for population vaccination.

Preclinical study data show that the vaccine can effectively induce high levels of serum bactericidal antibodies in the body, providing good cross-protection against Group B meningococcal strains prevalent in China, with excellent safety performance, laying a solid foundation for subsequent clinical trials.

Overview of Group B Meningococcal Vaccine Development in China: Three Major Technical Routes Racing, Multiple Products Enter Clinical Stage

In fact, Simcere Xiangrui is not the only domestic company布局B群流脑疫苗. In recent years, with the increasing urgency of meningococcal disease prevention and control in China, more than a dozen local companies have entered this field, formingMulticomponent recombinant protein, Engineered outer membrane vesicles (OMV), Self-amplifying mRNAA development pattern featuring three major technological routes in parallel competition has taken shape, with multiple products already entering the critical clinical stage, and the dawn of domestic substitution is beginning to appear.

China's Core In-House R&D Pipeline for Group B Meningococcal Vaccines (As of May 2026)

Comparison and Analysis of Three Major Technical Routes

1. Multi-component recombinant protein (mainstream approach): The most technically mature and safest option, which is also easy to scale up for production, is the preferred route for currently marketed Group B meningococcal vaccines worldwide and for most products under research. The core advantage of China-produced products lies in the targeted optimization of antigen design, tailored to locally prevalent strains in China, offering more precise protection.

2. Engineered OMV (Innovative Route): The core advantage lies in preserving the conformation and immunogenicity of natural membrane proteins, inducing both humoral and cellular immunity without the need for adjuvants, offering broader protection. Y-Guan Bio's DX-104 is a leading player in this approach in China, with its R&D progress at the forefront of the industry.

3. Self-amplifying mRNA (Frontier Route): It has the advantages of a short R&D cycle, rapid response to strain mutations, strong immunogenicity, and significant dose-sparing effects, making it an important direction for future vaccine development. The preclinical data of Ningbo Junjian Bio's related products are impressive, with the potential to achieve technological leapfrogging.

Industry Outlook: 2028-2030 to Welcome Concentrated Launch Period of Vaccines Produced in China

As the relevant pipelines of companies such as Zhifei Green Bamboo, Yiguan Bio, and Simcere Xiangrui have successively entered the clinical stage, the development of domestically produced Group B meningococcal vaccines in China has officially entered an acceleration phase. Based on the current progress of various pipelines, the industry generally expects...2028-2030 Will See the Concentrated Market Launch of China-Produced Group B Meningococcal Vaccines, which will completely change the situation where China relies on imports for Group B meningococcal vaccines.

The market launch of China-produced Group B meningococcal vaccine will have profound public health implications and industrial value, mainly reflected in four aspects:

Completely Fill the Domestic Gap: Improve the serogroup coverage of meningococcal vaccines in China, build a "full-spectrum" meningitis prevention and control system, and address the shortcomings in public health prevention.

Greatly Improve Accessibility: The full-course vaccination cost has been reduced from over 3000 yuan to within 1000 yuan, significantly alleviating the financial burden on families for vaccinations, allowing more children to receive effective protection;

Break the Import Monopoly: With the advantages of localized protection and price, domestically produced vaccines are expected to quickly capture more than 90% of the market share, achieving full domestic substitution;

Promote Industrial Upgrading: Drive the iterative development of cutting-edge vaccine technologies such as recombinant proteins, OMV, and mRNA in China, further enhancing the overall competitiveness and international influence of China's vaccine industry.

The acceptance of Simcere Xiangrui's recombinant Group B meningococcal vaccine by the CDE marks another significant milestone in the development of domestically produced Group B meningococcal vaccines, demonstrating the breakthrough capabilities of local companies in vaccine innovation. We look forward to the smooth progress of clinical trials for the R&D pipelines of various companies, and hope for their early market entry to provide Chinese children with safe, effective, and accessible Group B meningococcal protection, safeguarding the healthy growth of the next generation.